Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection

Read, Tim R.H.; Jensen, Jørgen S.; Fairley, Christopher K.; Grant, Mieken; Danielewski, Jennifer A.; Su, Jenny; Murray, Gerald L.; Chow, Eric P.F.; Worthington, Karen; Garland, Suzanne M.; Tabrizi, Sepehr N.; Bradshaw, Catriona S.

i

Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection

Supporting Files Public Domain

Feb 2018
By Read, Tim R.H. ; Jensen, Jørgen S. ; Fairley, Christopher K. ; ...

File Language:

English

Details

Alternative Title:

Emerg Infect Dis
Personal Author:

Read, Tim R.H. ; Jensen, Jørgen S. ; Fairley, Christopher K. ; Grant, Mieken ; Danielewski, Jennifer A. ; Su, Jenny ; Murray, Gerald L. ; Chow, Eric P.F. ; Worthington, Karen ; Garland, Suzanne M. ; Tabrizi, Sepehr N. ; Bradshaw, Catriona S.
Description:

High levels of macrolide resistance and increasing fluoroquinolone resistance are found in Mycoplasma genitalium in many countries. We evaluated pristinamycin for macrolide-resistant M. genitalium in a sexual health center in Australia. Microbiologic cure was determined by M. genitalium-specific 16S PCR 14-90 days after treatment began. Of 114 persons treated with pristinamycin, infection was cured in 85 (75%). This percentage did not change when pristinamycin was given at daily doses of 2 g or 4 g or at 3 g combined with 200 mg doxycycline. In infections with higher pretreatment bacterial load, treatment was twice as likely to fail for each 1 log10 increase in bacterial load. Gastrointestinal side effects occurred in 7% of patients. Pristinamycin at maximum oral dose, or combined with doxycycline, cured 75% of macrolide-resistant M. genitalium infections. Pristinamycin is well-tolerated and remains an option where fluoroquinolones have failed or cannot be used.
Subjects:

Adult Anti-Bacterial Agents/pharmacology Drug Resistance, Multiple, Bacterial Female Humans Macrolides/pharmacology Male Mycoplasma Genitalium/drug Effects Mycoplasma Genitalium/genetics Mycoplasma Infections/drug Therapy Mycoplasma Infections/microbiology Pristinamycin/therapeutic Use Research
Source:

Emerg Infect Dis. 24(2):328-335.
Pubmed ID:

29350154
Pubmed Central ID:

PMC5782881
Document Type:

Journal Article
Volume:

24
Issue:

2
Collection(s):

Emerging Infectious Diseases
Main Document Checksum:

urn:sha256:60d8f81558507018a7246380b8974d06a932876238eba0ccea2272ec2a62d9f1
Download URL:

https://stacks.cdc.gov/view/cdc/51376/cdc_51376_DS1.pdf
File Type:

[PDF - 623.04 KB ]

File Language:

English

ON THIS PAGE

Details Supporting Files

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.